{"id":"bcg-tokyo-172-strain-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"BCG-itis (systemic BCG infection)"}]},"_chembl":{"chemblId":"CHEMBL2108905","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BCG Tokyo-172 works as an immunotherapeutic agent by activating dendritic cells and T cells through pattern recognition receptors, promoting a Th1-type immune response. This strain has been studied in combination with other immunotherapies to enhance anti-tumor activity, particularly in bladder cancer and other malignancies. The vaccine aims to prime the immune system to recognize and eliminate cancer cells.","oneSentence":"BCG Tokyo-172 is a live attenuated Mycobacterium bovis vaccine that stimulates innate and adaptive immune responses to enhance anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:44.669Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bladder cancer (non-muscle invasive)"},{"name":"Metastatic melanoma (in combination with other immunotherapies)"}]},"trialDetails":[{"nctId":"NCT03091660","phase":"PHASE3","title":"S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2017-02-24","conditions":"Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bacillus Calmette-Guerin Tokyo-172 Strain Vaccine"],"phase":"phase_3","status":"active","brandName":"BCG Tokyo-172 Strain Vaccine","genericName":"BCG Tokyo-172 Strain Vaccine","companyName":"SWOG Cancer Research Network","companyId":"swog-cancer-research-network","modality":"Biologic","firstApprovalDate":"","aiSummary":"BCG Tokyo-172 is a live attenuated Mycobacterium bovis vaccine that stimulates innate and adaptive immune responses to enhance anti-tumor immunity. Used for Bladder cancer (non-muscle invasive), Metastatic melanoma (in combination with other immunotherapies).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}